CClinicalTrials.gg
CompletedNCT05482009Updated Aug 1, 2022

Treatment of Angina Pectoris After Coronary Revascularization With Integrated Traditional Chinese and Western Medicine

An observational study in Angina Pectoris, sponsored by Jiangsu Famous Medical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-08-01.

Sponsored by Jiangsu Famous Medical Technology Co., Ltd. · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This study used a multicenter, prospective cohort study. According to whether they received TCM treatment and the degree of exposure to TCM, the cohorts were divided into strong TCM exposure group, TCM exposure group, weak TCM exposure group and Western medicine exposure group. The first three groups received traditional Chinese medicine treatment combined with western medicine basic treatment, and the cumulative treatment time of traditional Chinese medicine reached 80%, 30%-79% or 30% of the total course of treatment, respectively. The fourth group received basic western medicine treatment alone. Among them, Chinese medicines (including Chinese patent medicines, Chinese medicine decoctions, Chinese medicine granules, and Chinese medicine injections) have been used and/or taken for a total of 5 months;

Read the detailed description

The purpose of this study was to observe whether the combination of traditional Chinese medicine intervention on the basis of standardized western medicine treatment could further reduce the incidence of cardiovascular events in patients with angina pectoris after coronary revascularization compared with western medicine treatment, and to conduct objective follow-up. Evaluation of integrated Chinese and Western medicine interventions. Clinical efficacy of angina pectoris after coronary revascularization and characteristic advantages of TCM syndrome improvement.

The trial is a multicenter, prospective clinical cohort study design. It is expected that 2,000 subjects will be included, and they will be divided into 4 groups according to whether they receive Chinese medicine treatment and the degree of exposure to Chinese medicine. One group received only western medicine basic treatment, and the other three groups received Chinese medicine treatment combined with western medicine basic treatment (the difference was that the cumulative treatment time of Chinese medicine reached 80%, 30%-79% or 30% of the total course of treatment, respectively). Among them, Chinese medicines (including Chinese patent medicines, Chinese medicine decoctions, Chinese medicine granules, and Chinese medicine injections) have been used and/or taken for 5 months in total.

The duration of treatment (including follow-up) in this trial was 24 months. Study data were recorded at 0, 3, 6, 9, 12, 15, 18, 21, and 24 months.

02

Conditions studied

  • Angina Pectoris

Browse trials for

Keywords

  • Integrated Chinese and Western Medicine Treatment
  • Comprehensive Treatment
03

In context

Angina Pectoris

519 studies on the registry are indexed under Angina Pectoris; 82 are open to participants now.

This study's enrollment of 2,000 is above the median of 591 across 154 observational studies indexed under Angina Pectoris.

Browse Angina Pectoris studies →

Lead sponsor

Jiangsu Famous Medical Technology Co., Ltd. is the lead sponsor of 20 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients in tertiary hospitals

Inclusion criteria

  • ①Age ≥18 years old and ≤85 years old;

    • Patients who have undergone coronary revascularization (including coronary bypass and/or PCI) in the past.

      • Those who participated voluntarily and signed the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • ①Incomplete case data, unable to provide original surgical data entry;

    • Patients who meet the diagnostic criteria for coronary heart disease, angina pectoris or myocardial infarction, but have not undergone coronary revascularization or failed surgery;

      • Patients who still need continuous mechanical adjuvant therapy after successful coronary revascularization; ④ Combined with other heart diseases, such as malignant arrhythmia (rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia), or cardiac insufficiency before and after surgery (cardiac function class IV, NYHA class or Killip class), severe cardiopulmonary insufficiency .

        • Those who have a history of hemorrhagic cerebrovascular accident, or a history of ischemic cerebrovascular accident (including TIA) within half a year; ⑥Mental patients or those who may not be able to cooperate with the program requirements and follow-up procedures due to educational level, language barriers and other reasons.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
2,000 participants (actual)
Patient registry
No

Groups and cohorts

  • Strong exposure group of traditional Chinese medicine

    receiving traditional Chinese medicine treatment + basic western medicine treatment, the cumulative time of traditional Chinese medicine treatment reaches more than 80% of the total course of treatment

    Other: Traditional Chinese Medicine Treatment Combined with Western Medicine Basic Treatment

  • Moderate Chinese medicine exposure group

    received Chinese medicine treatment + western medicine basic treatment, the cumulative time of Chinese medicine treatment reached 30%-79% of the total course of treatment

    Other: Traditional Chinese Medicine Treatment Combined with Western Medicine Basic Treatment

  • Weak exposure group of traditional Chinese medicine

    receiving traditional Chinese medicine treatment + basic western medicine treatment, the cumulative time of traditional Chinese medicine treatment is less than 30% of the total course of treatment

    Other: Traditional Chinese Medicine Treatment Combined with Western Medicine Basic Treatment

  • Western medicine group

    receive basic western medicine treatment only

Interventions

  • OtherTraditional Chinese Medicine Treatment Combined with Western Medicine Basic Treatment

    The cumulative observation and treatment (including Chinese patent medicine, Chinese medicine decoction, Chinese medicine granule, Chinese medicine injection, and western medicine) were more than 5 months, and the follow-up was 1.5 years.

06

What researchers measure

Primary outcomes

  1. Incidence of MACE

    Major adverse cardiovascular events that may have occurred in subjects were recorded throughout the trial,and assessed 24 months after taking medicine.

    Time frame: Assess once 24 months after taking medicine

  2. Readmission rate

    Readmissions for cardiovascular disease were recorded throughout the trial,and assessed 24 months after taking medicine.

    Time frame: Assess once 24 months after taking medicine

Secondary outcomes

  1. Angina attack frequency scale

    Subjects were assessed using the Angina attack frequency scale at months 3, 6, 9, 12, 15, 18, 21, and 24. The minimum value is 0 and the maximum value is 6. Higher scores indicate worse subjects.

    Time frame: 3 months

  2. Angina Attack Duration scale

    Subjects were assessed using the Angina Attack Duration scale at months3, 6, 9, 12, 15, 18, 21, and 24. The minimum value is 0 and the maximum value is 6. Higher scores indicate worse subjects.

    Time frame: 3 months

  3. Angina Pain scale

    Subjects were assessed using the Angina Pain scale at months 3, 6, 9, 12, 15, 18, 21, and 24. The minimum value is 0 and the maximum value is 6. Higher scores indicate worse subjects.

    Time frame: 3 months

  4. Nitroglycerin Dosage scale

    Subjects were assessed using the Nitroglycerin Dosage scale at months 3, 6, 9, 12, 15, 18, 21, and 24. The minimum value is 0 and the maximum value is 6. Higher scores indicate worse subjects.

    Time frame: 3 months

  5. The Seattle angina questionaire

    Subjects were assessed using the Seattle Angina Questionnaire at months 0, 3, 6, 9, 12, 15, 18, 21, and 24. The minimum value is 0 and the maximum value is 100. Higher scores indicate better subjects.

    Time frame: 3 months

  6. NYHA classification

    Subjects were assessed at 0, 3, 6, 9, 12, 15, 18, 21, and 24 months using NYHA classification. Results include grades I, II, III, and IV.Higher Class indicate worse subjects.

    Time frame: 3 months

  7. Traditional Chinese medicine syndrome rating scale

    On the 0th, 3rd, 6th, 9th, 12th, 15th, 18th, 21st, and 24th months, the subjects were evaluated using the TCM syndrome score table, and the evaluation results were judged as markedly effective, effective, ineffective or aggravated.

    Time frame: 3 months

  8. Patient Health Questionaire-9 scale

    On the 0th, 3rd, 6th, 9th, 12th, 15th, 18th, 21st, and 24th months,Subjects were assessed using the Patient Health Questionaire-9 scale with a minimum of 0 and a maximum of 27. Higher scores indicate worse subjects.

    Time frame: 3 months

  9. Generalized Anxiety Disorder -7 scale

    On the 0th, 3rd, 6th, 9th, 12th, 15th, 18th, 21st, and 24th months,Subjects were assessed using theGeneralized Anxiety Disorder -7 scale with a minimum of 0 and a maximum of 21. Higher scores indicate worse subjects.

    Time frame: 3 months

07

Study locations

1 site
  • Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
    Shenyang, Liaoning 110000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05482009
Lead sponsor
Jiangsu Famous Medical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Aug 1, 2022
Start date
Jun 1, 2019
Primary completion
Dec 31, 2021
Completion
Jun 30, 2022
Last update
Aug 1, 2022

Study contacts

Shuai Wang, master
principal investigator · First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion